FDA issues no new esketamine (Spravato) safety communication tied to the BPD suicidality cohort finding, but references it in updated REMS discussion materials.

Spravato (esketamine) is a nasal spray version of ketamine approved to treat severe depression — it's the closest thing currently on the market to a legal psychedelic-adjacent mental health drug. A study found higher rates of suicidal thoughts in one specific group of patients using it. However, the FDA (the US drug regulator) is not expected to issue a new public safety warning, because the data likely reflects the fact that those patients were already more severely ill — not that the drug caused the problem. Instead, the FDA will probably quietly update its REMS (Risk Evaluation and Mitigation Strategy — a special safety management program) educational materials to mention the finding.

The covariance with depressive severity signals confounding, not drug-induced risk. FDA won't act on observational data, but will fold it into ongoing REMS scrutiny.